Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

NCT02952729 is registered in ClinicalTrials.gov with Mersana Therapeutics as lead sponsor.

NCT NCT02952729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Lead sponsor
Mersana Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 21, 2016
Completion date
January 28, 2019
Enrollment
120 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced gastric cancer, advanced nonsmall cell lung cancer